Advertisement

Effect of Substance P on Human Lymphocyte Proliferation in Vitro: A Comparison between Normal and Birch Pollen Allergic Individuals

  • G. Nilsson
  • S. Rak
  • S. Ahlstedt
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 216 A)

Abstract

The hyperreactivity in allergic patients has been proposed to be a consequence of a wide range of effector mechanisms, including both the autonomous and the immune systems. In 1968, Szentivanyi proposed in his beta-adrenergic blockade theory that bronchial hyperreactivity and related atopic abnormalities might be caused by a decreased beta-adrenergic responsiveness (1). Such abnormality has also been found in the lymphocyte populations, which exhibit different reactivity to beta-adrenergic compounds compared with that of the cells of normal individuals (2). Lymphocytes from atopic patients also seem to have altered reactivity to mediators from inflammatory cells (3).

Keywords

Mast Cell Normal Individual Peripheral Blood Lymphocyte Allergic Patient Birch Pollen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Szentivanyi, A., J. Allergy 42, 203, 1968.CrossRefGoogle Scholar
  2. 2.
    Meurs, H., Koëter, G.H., de Vries, K. and Kauffman, H.F., J. Allergy Clin. Immunol. 70, 272, 1982.PubMedCrossRefGoogle Scholar
  3. 3.
    Beer, D.J., Osband, M.E., McCaffrey, R.P., Soter, N.A. and Rocklin, R.E., N. Engl. J. Med. 306, 454, 1982.PubMedCrossRefGoogle Scholar
  4. 4.
    Barnes, P.J., Thorax 39, 561, 1984.PubMedCrossRefGoogle Scholar
  5. 5.
    Lundberg, J.M., Hökfeldt, T., Martling, C.-R., Saria, A. and Cuello, C., Cell Tissue Res. 235, 251, 1984.PubMedCrossRefGoogle Scholar
  6. 6.
    Payan, D.G., Brewster, D.R., Missirian-Bastian, A. and Goetzl, E.J., J. Clin. Invest. 74, 1532, 1984.PubMedCrossRefGoogle Scholar
  7. 7.
    Hartung, H.P., Wolters, K., Stoll, G. and Toyka, K.V., in Substance P: Metabolism and Biological Actions, (Edited by Jordan, C.C. and Oehme, P.) p. 237, Taylor and Francis, London and Philadelphia, 1985.Google Scholar
  8. 8.
    Payan, D.G., Brewster, D.R. and Goetzl, E.J., J. Immunol. 131, 1613, 1983.PubMedGoogle Scholar
  9. 9.
    Stanisz, A.M., Befus, D. and Bienenstock, J., J. Immunol. 136, 152, 1986.PubMedGoogle Scholar
  10. 10.
    Liping, Z., Dan, C., Shuzhen, Z. and Shilian, L., Immunol. Commun. 13, 457, 1984.Google Scholar
  11. 11.
    Piotrowski, W., Devoy, M.A.B., Jordan, C.C. and Foreman, J.C., Agents and Actions 14, 420, 1984.PubMedCrossRefGoogle Scholar
  12. 12.
    Shanahan, F., Denburg, J.A., Fox, J., Bienenstock, J. and Befus, J., J. Immunol. 135, 131, 1985.Google Scholar
  13. 13.
    Payan, D.G., Levine, J.D. and Goetzl, E.J., J. Immunol. 132, 1601, 1984.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • G. Nilsson
    • 1
    • 2
  • S. Rak
    • 1
    • 2
  • S. Ahlstedt
    • 1
    • 2
  1. 1.Department of Immunology, Pharmacia Diagnostics AB, Uppsala, Lung ClinicCentral HospitalVästeråsSweden
  2. 2.Department of Clinical ImmunologyUniversity of GothenburgGothenburgSweden

Personalised recommendations